More news
- PPG completes Colorful Communities project in Poland
- BASF and University of California, Berkeley, celebrate their successful 10-year collaborat...
- Axalta products win Silver 2024 Edison Awards
- IMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma
- PPG reports results for Q1, 2024
Royal DSM reported Q2 2014 EBITDA from continuing operations of €293M compared to €332M in Q2 2013 and €272M in Q1 2014. Nutrition showed improvement compared to the last two quarters. Performance Materials continued its encouraging underlying trend and delivered higher results. Polymer Intermediates was negatively impacted by lower caprolactam margins.
Commenting on the results, Feike Sijbesma, CEO/ Chairman of the DSM Managing Board, said: "DSM delivered improved results versus the first quarter, despite persistent currency headwinds. Performance Materials saw continued positive momentum in a number of end-markets, whereas Polymer Intermediates has seen weaker business conditions for caprolactam.
